Sara Tabatabai

Sara Tabatabai

Auto-generated profile, based on publicly available information

Sara Tabatabai

Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center , New York, NY

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 November 2020 in Annals of Internal Medicine
Verified
Journal Article
Closed access
AMAaron P. Mitchell
Aaron P. Mitchell
NTNiti U. Trivedi
Niti U. Trivedi
RGRenee L. Gennarelli
Renee L. Gennarelli
SCSusan Chimonas
Susan Chimonas
STSara M. Tabatabai
Sara M. Tabatabai
DKDeborah Korenstein
Deborah Korenstein
This systematic review of 36 studies examines associations between industry payments and physician prescribing. Background: Financial payments from the drug industry to U.S. physicians are common. Payments may influence physicians' clinical decision making and drug prescribing. Purpose: To evaluate whether r...

10 February 2025 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
AMAaron P. Mitchell
Aaron P. Mitchell
SPSonia Persaud
Sonia Persaud
AMAkriti Mishra Meza
Akriti Mishra Meza
HFHannah E. Fuchs
Hannah E. Fuchs
PDPrabal De
Prabal De
MGMithat Gönen
Mithat Gönen
PURPOSE: The Medicare part D Low-Income Subsidy (LIS) improves access to oral cancer drugs, but provides no assistance for clinician-administered/part B drugs. This analysis assessed the association between LIS participation and receipt of optimal cancer treatment. METHODS: We investigated initial systemic therapy using SEER-Medicare data (2015-2017) and National Comprehensive Cancer Network (NCCN) Evidence Blocks (EB) as the standard for treatment recommendations. We included cancer clinical scenarios wherein (1) ≥one treatment was optimal (higher efficacy and safety scores) versus other treatments; (2) identifiable in SEER-Medicare (eg, not defined by clinical data unavailable in registry data or claims); and (3) both EB and ASCO Value Framework agreed regarding optimal treatment. We fit logistic regression models to assess the association between receipt of systemic therapy ( v no therapy) and patient and provider characteristics. Contingent on receipt of treatment, we modeled the likelihood of receiving a treatment ranked (by EB scores) within the highest or lowest quartile for that cancer type. RESULTS: Nine thousand two hundred and ninety patients were included across 11 clinical scenarios. Fifty-seven percent (5,336) of patients received any systemic therapy and 43% (3,954) received no systemic therapy. Compared with non-LIS participants, LIS participants were less likely to receive any systemic therapy versus no systemic therapy (odds ratio, 0.64 [95% CI, 0.57 to 0.72]). Contingent on receiving systemic therapy, LIS participants received treatment ranked within the worst quartile 24.8% of the time, compared with 21.9% of non-LIS patients (adjusted prevalence difference, 4.3% [95% CI, 0.5 to 8.2]). CONCLUSION: LIS participants were less likely to receive systemic therapy at all and were more likely to receive treatments that receive low NCCN EB scores.

1 April 2024 in JCO Clinical Cancer Informatics
Verified
Journal Article
Closed access
JBJenna Bhimani
Jenna Bhimani
KOKelli O'COnnell
Kelli O'COnnell
IEIsaac J. Ergas
Isaac J. Ergas
MFMarilyn Foley
Marilyn Foley
GGGrace B. Gallagher
Grace B. Gallagher
EKElizabeth D. Kantor
Elizabeth D. Kantor
PURPOSE: Identification of patients' intended chemotherapy regimens is critical to most research questions conducted in the real-world setting of cancer care. Yet, these data are not routinely available in electronic health records (EHRs) at the specificity required to address these questions. We developed a methodology to identify patients' intended regimens from EHR data in the Optimal Breast Cancer Chemotherapy Dosing (OBCD) study. METHODS: In women older than 18 years, diagnosed with primary stage I-IIIA breast cancer at Kaiser Permanente Northern California (2006-2019), we categorized participants into 24 drug combinations described in National Comprehensive Cancer Network guidelines for breast cancer treatment. Participants were categorized into 50 guideline chemotherapy administration schedules within these combinations using an iterative algorithm process, followed by chart abstraction where necessary. We also identified patients intended to receive nonguideline administration schedules within guideline drug combinations and nonguideline drug combinations. This process was adapted at Kaiser Permanente Washington using abstracted data (2004-2015). RESULTS: In the OBCD cohort, 13,231 women received adjuvant or neoadjuvant chemotherapy, of whom 10,213 (77%) had their intended regimen identified via the algorithm, 2,416 (18%) had their intended regimen identified via abstraction, and 602 (4.5%) could not be identified. Across guideline drug combinations, 111 nonguideline dosing schedules were used, alongside 61 nonguideline drug combinations. A number of factors were associated with requiring abstraction for regimen determination, including: decreasing neighborhood household income, earlier diagnosis year, later stage, nodal status, and human epidermal growth factor receptor 2 (HER2)+ status. CONCLUSION: We describe the challenges and approaches to operationalize complex, real-world data to identify intended chemotherapy regimens in large, observational studies. This methodology can improve efficiency of use of large-scale clinical data in real-world populations, helping answer critical questions to improve care delivery and patient outcomes.

1 February 2025 in JCO Clinical Cancer Informatics
Verified
Journal Article
Closed access
PWPeng Wang
Peng Wang
KOKelli O'COnnell
Kelli O'COnnell
JBJenna Bhimani
Jenna Bhimani
VBVictoria Blinder
Victoria Blinder
RBRachael Burganowski
Rachael Burganowski
EKElizabeth D. Kantor
Elizabeth D. Kantor
PURPOSE: We evaluated the definitions of five comorbidities (renal and hepatic impairments, anemia, neutropenia, and thrombocytopenia) in women with breast cancer using data from electronic health records. METHODS: In 11,097 women receiving adjuvant chemotherapy for stage I-IIIA breast cancer at Kaiser Permanente Northern California or Kaiser Permanente Washington, we assessed comorbidity definitions in two commonly used lookback windows (1 year before diagnosis, T1; and extending until chemotherapy initiation, T1-2). Within each, we assessed data availability and agreement between International Classification of Diseases (ICD)–defined and lab-defined comorbidities of varying severity. To assess how different pieces of information may affect providers in making treatment decisions, we used multivariable logistic regression to evaluate four-category (with comorbidity indicated by both ICD and lab, ICD-only, lab-only, or neither) and collapsed binary (comorbidity indicated by either ICD or lab v neither) definitions in relation to first cycle chemotherapy dose reduction (FCDR). RESULTS: Extending the lookback period to chemotherapy initiation increased laboratory data availability (missingness ≤4.1% in T1-2 v >40% in T1). Assessment of agreement guided selection of laboratory cutpoints. In both time periods, the four-category and binary comorbidity variables were associated with use of FCDR, but binary variables had larger cell sizes and more stability of regression models. Ultimately, the comorbidity variables in T1 were defined by a combination of either ICD/qualifying laboratory values. Results were similar in T1-2, except laboratory data alone outperformed the combination variable for renal and hepatic comorbidity. CONCLUSION: Leveraging both ICD and lab data and extending the lookback period to include postdiagnosis but prechemotherapy initiation may provide better capture of comorbidity. Future studies may consider validating our findings with a gold-standard comorbidity status and in other community health care settings.

5 November 2025 in BMJ
Verified
Journal Article
Open access
PDF file
AMAaron P Mitchell
Aaron P Mitchell
SDStacie B Dusetzina
Stacie B Dusetzina
AMAkriti Mishra Meza
Akriti Mishra Meza
GGGrace Gallagher
Grace Gallagher
PAPatrick Augello
Patrick Augello
MGMithat Gönen
Mithat Gönen
Objective To estimate the association between the billing (profit) margin and clinical benefit of cancer treatments and use by oncologists. Design Retrospective population based cohort study Setting Population based sample using fee-for-service Medicare claims data. Participants Medicare beneficiaries with an incident cancer diagnosis from 2015 to 2020; included all patients with cancer treatment indications for which the available treatment options varied in clinical benefit and billing margin. Main outcomes and measures The primary outcome was the cancer treatment each patient received among treatment options recommended by the National Comprehensive Cancer Network (NCCN). The characteristics of interest were provider billing margin (defined at the patient treatment level, using Medicare reimbursement rates corresponding to the patient’s diagnosis date) and a proxy measure of clinical benefit (rank order of treatments based on Evidence Blocks scores developed by the NCCN, corresponding to the patient’s diagnosis date). The association between treatment received, billing margin, and clinical benefit was modeled using a conditional logit model with inverse probability-of-treatment weights applied at the patient treatment level to control for patient and provider characteristics. Results Twelve cancer indications were examined comprising 19 397 individual patients. Provider billing margin ranged from $0 to $12 692 (£9440; €10 800) for each course of treatment. No association was found between a $100 increase in provider billing margin and the likelihood of treatment use (odds ratio 0.97, 95% confidence interval 0.91 to 1.03). Higher clinical benefit was associated with greater treatment use (1.62, 1.15 to 2.29). Conclusions In this observational study of Medicare beneficiaries, selection of cancer treatments was associated with the treatment’s clinical benefit but not billing margin. Therefore, it is unlikely that policy and price changes that affect the billing margin of cancer treatments would shift patterns of use.

25 July 2024 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Closed access
PDF file
JBJenna Bhimani
Jenna Bhimani
KOKelli O’cOnnell
Kelli O’cOnnell
SPSonia Persaud
Sonia Persaud
VBVictoria Blinder
Victoria Blinder
RBRachael P. Burganowski-Doud
Rachael P. Burganowski-Doud
EKElizabeth D. Kantor
Elizabeth D. Kantor
Background: Guidelines informing chemotherapy regimen selection are based on clinical trials with participants who do not necessarily represent general populations with breast cancer. Understanding who receives nonguideline regimens is important for understanding real-world chemotherapy administration and how it relates to patient outcomes. Methods: Using data from the Optimal Breast Cancer Chemotherapy Dosing (OBCD) study, based at Kaiser Permanente Northern California (2006–2019) and Kaiser Permanente Washington (2004–2015), we use logistic regression to examine the associations between patient characteristics and receipt of nonguideline chemotherapy regimens among 11,293 women with primary stage I to IIIA breast cancer receiving chemotherapy. Results: The use of nonguideline regimens was strongly associated with several factors, including older age [≥80 vs. 18–39 years: OR, 5.25; 95% confidence interval (CI), 3.06–9.00; P-trend = 0.002] and HER2 status (HER2+ vs. HER2−: OR, 3.44; 95% CI, 3.06–3.87) and was less likely in women with larger tumor size (>5 cm vs. 0.1 to ≤0.5 cm: OR, 0.56; 95% CI, 0.36–0.87; P-trend = 0.01) and diagnosed in later years (2012–2019 vs. 2005–2011: OR, 0.80; 95% CI, 0.71–0.90). Factors associated varied by type of nonguideline regimens. For example, women with comorbidity and older age were more likely to receive nonguideline drug combinations in particular, whereas women with larger tumor size were less likely to receive nonguideline administration schedules. Conclusions: Nonguideline chemotherapy regimens are more likely in certain patient populations. Impact: These associations highlight that vulnerable patient populations may be less likely to receive guideline care, and thus, real-world studies are essential for understanding how the use of nonguideline regimens impacts patient outcomes in these groups.